Nuritas Valuation, Funding & Investors
Nuritas is valued at $96M as of December 2017.
Last Nuritas valuation
$96M
Series A · Dec 2017
Last Nuritas funding round
$42M
Series C · Dec 2024
Cumulative funding Nuritas raised
$111M
across 5 funding rounds
Key investors in Nuritas
Enterprise Ireland
Grosvenor Food & AgTech
Cultivian Sandbox Ventures
European Circular Bioeconomy Fund
Clay Capital
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>)
Marc Benioff
About Nuritas
Nuritas is a Dublin-headquartered peptide discovery company using AI and genomics to identify bioactive peptides from food sources for skin health and inflammation management. Its Nov Daily peptide targets aging skin and is sold via partnerships with cosmetic brands worldwide.
Founded
2014
HQ
DublinWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
Valuation
$96M (Dec 2017)
Nuritas Valuation
Nuritas is currently valued at $96M, based on its Series A in December 2017.
The $19M round was led by Cultivian Sandbox Ventures, with participation from Enterprise Ireland and Sandbox Industries.
Nuritas valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Dec 2017 | Series A | $96M |
Nuritas Funding History
Nuritas has raised a total of $111M across 5 funding rounds.
Nuritas' first fundraising round was a $100K pre-seed round in April 2014. The most recent completed round was a $42M Series C in December 2024.
Nuritas funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Dec 2024 | Series C | M&G Investments (lead); European Circular Bioeconomy Fund; McWin Partners; Grosvenor Food & AgTech | $42M | - | Nuritas, an Irish biotech company founded in 2014 by Dr. Nora Khaldi, uses its AI-powered Magnifier platform to discover novel bioactive peptides from plant materials for health and nutrition applications in foods, beverages, supplements, cosmetics, and more. The company targets preventative health benefits, sustainability, and global impact, partnering with major firms like Givaudan, BASF, Nestlé, Mars, and Sumitomo Corporation. On December 20, 2024, Nuritas closed an oversubscribed $42 million Series C funding round led by M&G Investments on behalf of its Catalyst strategy, with participation from new investor McWin Capital Partners and existing investors Grosvenor Food & AgTech and European Circular Bioeconomy Fund (ECBF). This brings total funding to approximately $117 million to nearly $150 million across 10 rounds, following a $45 million Series B three years prior. M&G's Alex Seddon and McWin's Henry McGovern joined the board. The funds will scale operations, expand global market penetration, develop more ingredients and formulations, grow the B2B customer base, and launch products targeting health challenges in Europe and Asia by 2025. Nuritas is transitioning from technology and scientific development to commercial launches across pharmacies, retail, online, and specialty stores, emphasizing accessible healthier, sustainable ingredients. Backed early by U2's Bono and The Edge, Nuritas leverages clinical trials to lead in AI peptide discovery, addressing high costs and risks in the field. The investment supports transformative solutions for social and environmental challenges while seeking financial returns through M&G's £126 billion With Profits Fund. |
| Nov 2021 | Series B | Cleveland Avenue (lead); European Circular Bioeconomy Fund; Cultivian Sandbox Ventures; Veronorte; CJ; Grosvenor Food & AgTech; Clay Capital; Vertex Venture Holdings | $45M | - | Nuritas, a Dublin-based biotechnology company, specializes in AI-powered discovery and development of plant-based bioactive peptides from everyday foods for health and nutrition applications, using its proprietary Nπϕ platform and the world's largest peptide knowledge base. The company closed a $45 million USD Series B funding round on November 11, 2021, led by Cleveland Avenue, with participation from Grosvenor’s Wheatsheaf Group, European Circular Bioeconomy Fund, Vertex Holdings, Nutresa Ventures/Veronorte, CJ, and existing investors Cultivian Sandbox Ventures and VisVires New Protein. This brought total funding to $75 million USD following a prior €16 million Series A in 2017. The funding supports global expansion, including establishing a US headquarters, scaling the peptide discovery platform, expanding the team, growing the commercial operations, and accelerating route-to-market for life-changing ingredients. Nuritas has partnerships with major customers like Nestlé, Mars, Sumitomo, and Pharmavite, focusing on healthier, safer, and more sustainable products in food and health industries. The round added Randall Lewis from Cleveland Avenue and Stephan Dolezalek from Grosvenor’s Wheatsheaf Group to the board, with Indra Nooyi joining the advisory board. Early backers include U2's Bono and The Edge, Salesforce CEO Marc Benioff, and Ali Partovi. A later $42 million Series C round was raised, led by M&G Investments with McWin Capital Partners and others, but details remain separate from the 2021 Series B. |
| Dec 2017 | Series A | Cultivian Sandbox Ventures (lead); Enterprise Ireland; Sandbox Industries | $19M | $96M | Nuritas is an Irish biotechnology company founded in 2014 by Nora Khaldi, specializing in using artificial intelligence and genomics to discover bioactive peptides from food sources for health benefits, particularly targeting conditions like pre-diabetes and diabetes. The company analyzes peptides 500 times faster than traditional methods to develop ingredients for supplements, functional foods, and cosmetics. On December 20, 2017, Nuritas closed a Series A funding round of US$20 million (equivalent to €16 million) led by Cultivian Sandbox Ventures, with participation from Enterprise Ireland and others, bringing total funding to approximately US$30 million including prior investments from U2's Bono and The Edge, Marc Benioff, and VisVires New Protein. The 2017 round aimed to support U.S. market expansion, research into diabetes and other societal health issues, international growth, and hiring up to 50 staff in Ireland. At the time, Nuritas employed about 30 people in Ireland and had breakthroughs like a peptide against MRSA, with partnerships later emerging with companies like Nestlé and Mars. Subsequent rounds include a $45 million Series B in 2021 led by Cleveland Avenue for scaling plant-based peptides and global launches, and a Series C in 2024 raising USD 42 million led by M&G Investments. Nuritas continues focusing on products like PeptiYouth™ and PeptiStrong™ for wellness, with U.S. headquarters plans and B2C explorations. |
| Dec 2015 | Seed | Clay Capital (lead); Enterprise Ireland; Marc Benioff; Ali Partovi | $5M | - | Nuritas is a Dublin-based biotechnology company founded by Dr. Nora Khaldi that uses artificial intelligence and DNA sequencing to discover bioactive peptides from natural sources like food for applications in therapeutics, functional foods, pharmaceuticals, dietary supplements, and cosmetics. The company identifies molecules with scientifically validated health benefits, such as addressing inflammation, diabetes, ageing, and MRSA, at ten times faster speed and lower cost than traditional methods. In late 2015 to early 2016, Nuritas completed early funding rounds including a $3.2 million first round led by New Protein Capital with participation from Ali Partovi, setting an Irish record for initial investment in the space. A subsequent Series A round of $3.4 million was also led by New Protein Capital (noted as Clay Capital in some profiles), with Ali Partovi, building on prior pre-seed funding of $100k and self-funding. These rounds supported team expansion from 10 people, database growth, and initial commercialization efforts. Investors aligned with Nuritas' vision of unlocking nature's hidden health secrets through AI-driven discovery. The company had already patented ingredients and generated some early revenues via custom identification services for food companies, though it shifted focus to direct ingredient sales. Later rounds included Enterprise Ireland among current investors and Marc Benioff as an early backer in subsequent financings. |
| Apr 2014 | Pre-seed | NDRC (lead) | $100K | - | - |
Who has invested in Nuritas?
15 investors have backed Nuritas across its funding rounds, including Enterprise Ireland, Grosvenor Food & AgTech, Cultivian Sandbox Ventures, European Circular Bioeconomy Fund, Clay Capital and Marc Benioff.
Lead investors include M&G Investments, Cleveland Avenue, Cultivian Sandbox Ventures, Clay Capital and NDRC.
Nuritas Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
 Bonn | 2 | Participant | Nov 2021 | |
 Chicago, IL | 2 | Lead | Dec 2017 | |
 London | 2 | Participant | Nov 2021 | |
| Dublin | 2 | Participant | Dec 2015 | |
 Singapore | 2 | Lead | Dec 2015 | |
| Chicago, IL | 1 | Lead | Nov 2021 | |
 Medellín | 1 | Participant | Nov 2021 | |
 Seoul | 1 | Participant | Nov 2021 | |
 Prague | 1 | Participant | Dec 2024 | |
| London | 1 | Lead | Dec 2024 | |
| Chicago, IL | 1 | Participant | Dec 2017 | |
| Dublin | 1 | Lead | Apr 2014 | |
| Marc Benioff | San Francisco, CA | 1 | Participant | Dec 2015 |
This data is available for Pro users. Sign up to see all 15 Nuritas investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialNuritas Competitors
Nuritas competitors include listed companies like Pluszero and Heroz, and private ones like Anterior, Mother Nature Ai, Yewno and Zhongying Shuzhi.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 Japan | Publicly listed | $10M | $4M | $96M | 7.4x | |
| New York City, NY | Private | - | - | $95M | - | |
| New York City, NY | Private | - | - | $95M | - | |
| San Francisco, CA | Private | - | - | $95M | - | |
 Hangzhou | Private | - | - | $98M | - | |
| Japan | Publicly listed | $41M | $8M | $94M | 2.1x |
Nuritas Public Comps
Nuritas is still privately-owned, but its public comps include Pluszero, Promopharm, Heroz, Laboro AI, 4basebio, Curiosis, FitLife Brands, Hyundai Bioland Co, tripla and Vita Life Sciences.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $10M | $4M | 8.8x | 7.4x | 23.5x | - | |||
| $103M | $12M | 0.9x | - | 7.4x | - | |||
| $41M | $8M | 2.1x | 2.1x | 11.7x | 13.7x | |||
| $12M | $2M | 6.4x | 6.4x | 49.0x | - | |||
| $2M | ($22M) | 43.3x | 29.6x | (4.5x) | (4.8x) | |||
| $5M | ($5M) | 15.2x | 8.7x | (16.3x) | (45.9x) | |||
| $81M | $10M | 1.6x | 1.3x | 12.2x | 8.5x | |||
| $95M | $12M | 0.8x | - | 6.0x | - | |||
This data is available for Pro users. Sign up to see all Nuritas competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Nuritas
| When was Nuritas founded? | Nuritas was founded in 2014. |
| Where is Nuritas headquartered? | Nuritas is headquartered in Dublin, Ireland. |
| Is Nuritas publicly listed? | No, Nuritas is a private, VC-backed company. |
| What is Nuritas' valuation? | Nuritas was last valued at $96M in its Series A in December 2017. |
| How much funding has Nuritas raised? | Nuritas has raised $111M across 5 funding rounds. |
| What was Nuritas' last funding round? | Nuritas' last funding round was a $42M Series C in December 2024, led by M&G Investments. |
| Who are Nuritas' investors? | Nuritas' investors include European Circular Bioeconomy Fund, Cultivian Sandbox Ventures, Grosvenor Food & AgTech, Enterprise Ireland, Clay Capital, Cleveland Avenue, Veronorte, CJ, McWin Partners, M&G Investments and 5 others. |
| Which companies are comparable to Nuritas? | Companies comparable to Nuritas include Pluszero, Anterior, Mother Nature Ai, Yewno, Zhongying Shuzhi and Heroz. |
See companies similar to Nuritas
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.